Xphyto Therapeutics (XPHY.C) provided a market and product update on its Rotigotine transdermal (TDS) patch, originally developed by their German subsidiary, Vektor Pharma TF GmbH.
If you’re interested in Xphyto and you’re here for it then feel free to skip the next few paragraphs. If you’re new to Xphyto, or this particular industry, then read on.
First, Xphyto Therapeutics is a biotech firm focused on developing next gen drug formulation, diagnostic and active pharmaceutical ingredient investment opportunities. This includes precision TD and oral dissolvable drugs, as well as rapid, low-cost infectious disease and oral health screening tests. They’re also involved in psychedelics for neurological conditions. They have spread out their research and development to North America and Europe, with a focus in Germany.
Rotigotine is treatment for Parkinson’s disease and restless leg syndrome in Europe and the United States. The drug doesn’t get absorbed well through pill form and has been remade into a transdermal patch taken once a day, which increases the rate of absorption and provides a slow and steady release over the drug over the course of a day.
The company finished a human bioavailability study for its Rotigotine TDS product. It had been a two week long study as an open-label, randomized, crossover, two-period and two-sequence, single dose pilot study to determine the level of its bioavailability when compared to the name brand. The study is now pushing the product towards a final study in Q4 2022 and will apply to regulators based on the results of that study.
In the meantime, they’ve recently completed a human cadaver skin permeation study at Vektor’s lab and manufacturing facility in Baden-Wurttemberg, Germany. The intend behind this is to compare Rotigotine’s absorption rate with two other derivative formulas and the name brand product. Results should be in about two weeks.
The market for this particular product is competitive and there hasn’t been much success beyond the name brand product launched originally in 2007. Even such, global sales for the patches were approximately USD $518 million ain 2021 with the market expected to jump over the $766 million mark by 2030.
—Joseph Morton
